Kuros Biosciences received FDA 510(k) clearance to market MagnetOs Flex Matrix for use in the interbody space. As a result, it can now be used in any interbody space (cervical, thoracic, lumbar) and in any cage approved for use with a bone void filler.
MagnetOs Flex Matrix is the first Kuros product to receive interbody clearance, having already been cleared by FDA for use in posterolateral fusion. Due to its fibrillar and flexible structure, this open matrix bone graft promotes bone growth even in soft tissue by optimizing the effect of Kuros’ NeedleGrip surface technology.
Chris Fair, Chief Executive Officer of Kuros, said, “With this clearance, we have a substantial commercial opportunity to re-engage with surgeons who were previously unable to use our MagnetOs Flex Matrix product on-label for interbody procedures. Kuros will continue to develop our research and technology – thus further demonstrating how we are continuing to meet our strategic goals for the benefit of patients and our investors.”
Kuros Biosciences received FDA 510(k) clearance to market MagnetOs Flex Matrix for use in the interbody space. As a result, it can now be used in any interbody space (cervical, thoracic, lumbar) and in any cage approved for use with a bone void filler.
MagnetOs Flex Matrix is the first Kuros product to receive interbody clearance, having...
Kuros Biosciences received FDA 510(k) clearance to market MagnetOs Flex Matrix for use in the interbody space. As a result, it can now be used in any interbody space (cervical, thoracic, lumbar) and in any cage approved for use with a bone void filler.
MagnetOs Flex Matrix is the first Kuros product to receive interbody clearance, having already been cleared by FDA for use in posterolateral fusion. Due to its fibrillar and flexible structure, this open matrix bone graft promotes bone growth even in soft tissue by optimizing the effect of Kuros’ NeedleGrip surface technology.
Chris Fair, Chief Executive Officer of Kuros, said, “With this clearance, we have a substantial commercial opportunity to re-engage with surgeons who were previously unable to use our MagnetOs Flex Matrix product on-label for interbody procedures. Kuros will continue to develop our research and technology – thus further demonstrating how we are continuing to meet our strategic goals for the benefit of patients and our investors.”
Copy to clipboard 
